Active, not recruitingPhase 1NCT03500991

HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

Studying Atypical teratoid rhabdoid tumor

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Seattle Children's Hospital
Principal Investigator
Rebecca Ronsley, MD
Seattle Children's Hospital
Intervention
HER2-specific chimeric antigen receptor (CAR) T cell(biological)
Enrollment
10 enrolled
Eligibility
1-26 years · All sexes
Timeline
2018 – 2039

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03500991 on ClinicalTrials.gov

Other trials for Atypical teratoid rhabdoid tumor

Additional recruiting or active studies for the same condition.

See all trials for Atypical teratoid rhabdoid tumor →

← Back to all trials